Literature DB >> 24918967

Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension.

Julia Hoffmann1, Jochen Wilhelm, Leigh M Marsh, Bahil Ghanim, Walter Klepetko, Gabor Kovacs, Horst Olschewski, Andrea Olschewski, Grazyna Kwapiszewska.   

Abstract

RATIONALE: The development of pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary disease (COPD) is associated with increased morbidity.
OBJECTIVES: To elucidate whether vascular remodeling in a well-characterized PH-COPD and PH-IPF patient cohort results from similar or divergent molecular changes.
METHODS: Vascular remodeling of donor, PH-COPD, and PH-IPF pulmonary arteries was assessed. Laser capture microdissected pulmonary artery profiles in combination with whole genome microarrays were performed.
MEASUREMENTS AND MAIN RESULTS: Pulmonary arteries from patients with COPD and IPF with PH exhibited remodeling of vascular layers and reduction of lumen area. Pathway analyses comparing normalized gene expression profiles obtained from patients with PH-IPF or PH-COPD revealed the retinol and extracellular matrix (ECM) receptor interaction to be the most perturbed processes. Within the ECM-receptor pathway, differential regulation of 5 out of the top 10 results (collagen, type III, α-1; tenascin C; collagen, type VI, α-3; thrombospondin 2; and von Willebrand factor) were verified by real-time polymerase chain reaction and immunohistochemical staining.
CONCLUSIONS: Despite clinical and histologic vascular remodeling in all patients with PH-COPD and PH-IPF, differential gene expression pattern was present in pulmonary artery profiles. Several genes involved in retinol metabolism and ECM receptor interaction enable discrimination of vascular remodeling in PH-IPF or PH-COPD. This suggests that pulmonary arterial remodeling in PH-COPD and PH-IPF is caused by different molecular mechanisms and may require specific therapeutic options.

Entities:  

Keywords:  laser capture microdissection; microarrays; pulmonary hypertension; remodeling

Mesh:

Year:  2014        PMID: 24918967     DOI: 10.1164/rccm.201401-0037OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

Review 1.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

2.  Why we should care about the mysteries of pulmonary hypertension.

Authors:  Horst Olschewski
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

3.  MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor β inducing fibrotic responses.

Authors:  Javier Milara; Beatriz Ballester; M J Safont; Enrique Artigues; Juan Escrivá; Esteban Morcillo; Julio Cortijo
Journal:  Mucosal Immunol       Date:  2020-09-04       Impact factor: 7.313

Review 4.  Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.

Authors:  Keshava Rajagopal; Andrew J Bryant; Sandeep Sahay; Nancy Wareing; Yang Zhou; Lavannya M Pandit; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

5.  Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients.

Authors:  Mariana Muñoz-Esquerre; Daniel Huertas; Ignacio Escobar; Marta López-Sánchez; Rosa Penín; Victor Peinado; Joan Albert Barberà; María Molina-Molina; Frederic Manresa; Jordi Dorca; Salud Santos
Journal:  Lung       Date:  2015-03-21       Impact factor: 2.584

6.  Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients.

Authors:  Julia Hoffmann; Leigh M Marsh; Mario Pieper; Elvira Stacher; Bahil Ghanim; Gabor Kovacs; Peter König; Heinrike Wilkens; Hans Michael Haitchi; Gerald Hoefler; Walter Klepetko; Horst Olschewski; Andrea Olschewski; Grazyna Kwapiszewska
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-03       Impact factor: 5.464

7.  A Review of Transcriptome Analysis in Pulmonary Vascular Diseases.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Methods Mol Biol       Date:  2018

8.  Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.

Authors:  Katsutoshi Ando; Hiroshi Kuraishi; Tetsutaro Nagaoka; Takeo Tsutsumi; Yoshito Hoshika; Toru Kimura; Hiroki Ienaga; Yoshiteru Morio; Kazuhisa Takahashi
Journal:  Lung       Date:  2015-10-09       Impact factor: 2.584

9.  Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure.

Authors:  Edda Spiekerkoetter; Elena A Goncharova; Christophe Guignabert; Kurt Stenmark; Grazyna Kwapiszewska; Marlene Rabinovitch; Norbert Voelkel; Harm J Bogaard; Brian Graham; Soni S Pullamsetti; Wolfgang M Kuebler
Journal:  Pulm Circ       Date:  2019-11-20       Impact factor: 3.017

10.  Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis.

Authors:  Scott D Collum; Ning-Yuan Chen; Adriana M Hernandez; Ankit Hanmandlu; Heather Sweeney; Tinne C J Mertens; Tingting Weng; Fayong Luo; Jose G Molina; Jonathan Davies; Ian P Horan; Nick W Morrell; Javier Amione-Guerra; Odeaa Al-Jabbari; Keith Youker; Wenchao Sun; Jayakumar Rajadas; Paul L Bollyky; Bindu H Akkanti; Soma Jyothula; Neeraj Sinha; Ashrith Guha; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.